Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ rejection in kidney transplant patients. ENVARSUS is developed based on the companys proprietary, patented drug delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis out licensed the commercial rights of Envarsus MENA region, Canada and China. The company sells ENVARSUS XR to wholesalers, specialty pharmacies and other customers. Veloxis is headquartered in Copenhagen, Denmark.

Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Veloxis Pharma Raises USD60 Million in Debt Financing 10
Private Equity 11
Veloxis Raises USD60 Million in Private Placement of Notes 11
Partnerships 12
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 12
Licensing Agreements 13
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Equity Offering 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 18
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 19
Veloxis Pharmaceuticals A/S - Key Competitors 20
Veloxis Pharmaceuticals A/S - Key Employees 21
Veloxis Pharmaceuticals A/S - Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 14, 2018: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 23
Feb 27, 2018: Veloxis Pharmaceuticals Releases Annual Report for 2017 24
Nov 14, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2017 25
Aug 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Six Months of 2017 26
May 16, 2017: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2017 27
Feb 28, 2017: Veloxis Pharmaceuticals Releases Annual Report for 2016 28
Corporate Communications 29
Apr 03, 2018: Veloxis Appoints Morten Marott as Chief Financial Officer 29
Sep 20, 2017: Alastair McEwan Steps Down as Chief Operating Officer of Veloxis Pharmaceuticals 30
Sep 13, 2017: Veloxis Pharmaceuticals Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List Of Tables

List of Tables
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Deals By Therapy Area, 2012 to YTD 2018 8
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Veloxis Pharma Raises USD60 Million in Debt Financing 10
Veloxis Raises USD60 Million in Private Placement of Notes 11
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 12
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 13
Paladin Labs Enters into Licensing Agreement with Veloxis Pharma 14
Taiba Pharma Enters into Licensing Agreement with Veloxis Pharma 15
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 16
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 17
Veloxis Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 18
Veloxis Pharma Raises USD0.6 Million in Private Placement of Shares 19
Veloxis Pharmaceuticals A/S, Key Competitors 20
Veloxis Pharmaceuticals A/S, Key Employees 21
Veloxis Pharmaceuticals A/S, Subsidiaries 22

List Of Figures

List of Figures
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Veloxis Pharmaceuticals AS (VELO) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for

USD 250 View Report

Veloxis Pharmaceuticals A/S Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Veloxis Pharmaceuticals A/S Company Profile is a detailed strategic and analytical report on Veloxis Pharmaceuticals A/S. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Veloxis Pharmaceuticals A/S Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Veloxis Pharmaceuticals A/S Company Profile is a detailed strategic and analytical report on Veloxis Pharmaceuticals A/S. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by

USD 125 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available